When will tavapadon be available?

AbbVie submitted the New Drug Application to the FDA in September 2025, and the FDA decision is expected in the first half of 2026. If approved, the drug would likely be available by prescription within a few months of the decision. Insurance coverage and pricing have not yet been announced.

How is tavapadon different from existing dopamine agonists like pramipexole or ropinirole?

Older agonists primarily activate D2 and D3 dopamine receptors. Tavapadon is selective for D1 and D5 receptors, a different family. In the TEMPO trials, this selectivity translated into lower rates of impulse-control disorders (about 1.4 percent) and daytime sleep attacks compared to what is typically seen with D2/D3 agonists. It is also once-daily, where most older agonists are taken two or three times a day.

Does tavapadon work for early Parkinson's or only advanced disease?

Both. The TEMPO program included monotherapy trials (TEMPO-1 and TEMPO-2) in people with early Parkinson's not yet on levodopa, and an add-on trial (TEMPO-3) in people with motor fluctuations on levodopa. All three Phase 3 trials hit their primary endpoint, so the FDA submission covers both populations.

Will tavapadon replace levodopa?

No. Levodopa is still the most effective Parkinson's medication that exists. Tavapadon is positioned as an alternative starting medication for early Parkinson's (to delay levodopa) and as an add-on for people already on levodopa who still have OFF time. The long-term TEMPO-4 extension reported that about 90 percent of participants did not need to start or increase levodopa during 14 to 20 months of tavapadon treatment.

Are there still tavapadon trials recruiting?

The pivotal Phase 3 trials have completed enrollment, but the TEMPO-4 open-label extension and post-marketing studies may still be enrolling participants in some regions. You can search current dopamine agonist trials at Parkinson's Pathways to see what is open today.

Tavapadon: The New Parkinson's Drug Awaiting FDA Approval in 2026

Tavapadon is an oral once-daily Parkinson's drug from AbbVie. The FDA is expected to decide on it in the first half of 2026. If approved, it will be the first dopamine agonist with a meaningfully different mechanism since the 1990s.

Here is what the drug is, what the Phase 3 trials showed, when it might be available, and how to think about it alongside the medications you already know.

What Tavapadon Is

Tavapadon is a dopamine agonist, the same broad class as pramipexole (Mirapex), ropinirole (Requip), and the rotigotine patch (Neupro). But it works on different dopamine receptors than the older agonists. The brain has five known dopamine receptor families: D1, D2, D3, D4, and D5. Older agonists mostly activate D2 and D3. Tavapadon is selective for D1 and D5.

The receptor difference matters. The D2/D3 family is the part of the dopamine system most tied to the two worst side effects of older agonists: impulse-control disorders (compulsive gambling, shopping, eating, or sexual behavior) and sudden daytime sleep attacks. Tavapadon was designed to skip those receptors. The TEMPO trial data so far backs the theory, but it has not been confirmed in long-term real-world use or in a head-to-head trial against an older agonist.

It is also a partial agonist rather than a full one, which means it activates the receptor less intensely than dopamine itself. Partial activation may be part of why the trial side-effect profile looks milder than what is typical for D2/D3 agonists, but that is still a theory, not a proven mechanism.

Tavapadon is taken once a day. Most older agonists need to be taken two or three times a day, or worn as a patch that has to be moved daily. A once-daily pill is a real quality-of-life difference for older patients and for caregivers managing schedules.

Who Makes It and Why That Matters

Tavapadon came out of Cerevel Therapeutics, a neuroscience spin-out from Pfizer. AbbVie acquired Cerevel in 2024 for roughly 8.7 billion dollars, in large part because of tavapadon. AbbVie already sells the Parkinson's infusion therapies Duopa and Vyalev, so an oral once-daily option fits cleanly into their existing Parkinson's portfolio.

For families, that means a major pharmaceutical company with the resources to launch the drug widely is behind it. That usually translates to broader insurance coverage and patient-support programs at launch than a smaller biotech would manage.

The TEMPO Trial Program

Tavapadon's Phase 3 data comes from a coordinated set of four trials called the TEMPO program. All four are large, randomized, and well-designed. Three of them (TEMPO-1, TEMPO-2, and TEMPO-3) form the basis of the FDA submission. The fourth (TEMPO-4) is a long-term safety extension.

TEMPO-1 and TEMPO-2 (Early Parkinson's)

TEMPO-1 and TEMPO-2 tested tavapadon as a standalone medication in people with early Parkinson's who were not yet on levodopa. TEMPO-1 used fixed doses of 5 mg or 15 mg in 529 participants. TEMPO-2 used flexible dosing from 5 to 15 mg in 304 participants. Both ran 26 to 27 weeks.

Both trials hit their primary endpoint with strong margins. The standard Parkinson's motor scale used in trials, called the MDS-UPDRS, measures everyday function and motor symptoms. In TEMPO-1, the placebo group worsened slightly over the trial (a score change of about +1.8) while the 5 mg tavapadon group improved by about 9.7 points and the 15 mg group improved by about 10.2 points. The difference was highly statistically significant. TEMPO-2 produced a similar size of benefit.

For context, a 10-point improvement on this scale is something patients and families notice in daily life. It is not a small effect.

TEMPO-3 (Advanced Parkinson's on Levodopa)

TEMPO-3 was the most clinically important trial. It tested tavapadon as an add-on therapy in 507 people with Parkinson's who were already on levodopa and experiencing motor fluctuations, meaning OFF time between doses. Participants were 40 to 80 years old. Results were presented at the American Academy of Neurology meeting in 2025.

The primary endpoint was the change in good ON time, the hours per day when symptoms are controlled without troublesome involuntary movements (dyskinesia). Tavapadon added about 1.1 more hours of good ON time per day than placebo, with very strong statistical confidence. OFF time decreased by about 0.94 hours per day compared with placebo. Both results are meaningful in real-life terms; an extra hour of well-controlled function per day, every day, adds up.

The safety profile in TEMPO-3 was consistent with the earlier trials. Most side effects were mild or moderate.

TEMPO-4 (Long-Term Safety)

TEMPO-4 is an open-label extension that has now followed close to 1,000 participants from the earlier trials. Interim data presented at the same 2025 meeting reported the following rates of common side effects across roughly 14 to 20 months on the drug: nausea about 11 percent, dizziness about 10.6 percent, headache about 9.6 percent, falls about 9.2 percent, and constipation about 5.5 percent. None of those numbers are unusual for a Parkinson's medication.

The numbers that matter most are the ones that have historically driven people off the older dopamine agonists. In TEMPO-4, hallucinations occurred in about 6.3 percent of participants, somnolence in about 4.6 percent, and impulse-control disorders in about 1.4 percent. For comparison, impulse-control disorders are seen in roughly 14 to 17 percent of people on long-term pramipexole or ropinirole in published estimates. The tavapadon rate is not zero, but it is markedly lower.

One striking number from TEMPO-4: about 90 percent of participants who started tavapadon as monotherapy did not need to start or increase levodopa over 14 to 20 months. That is a meaningful delay for people who want to put off the long-term motor fluctuations of levodopa.

When the FDA Decides

AbbVie submitted the New Drug Application to the FDA on September 26, 2025. A standard FDA review takes about 10 months, which puts the expected decision in the first half of 2026. As of late May 2026, a formal approval announcement has not yet been confirmed publicly, but the timeline suggests it is imminent or pending.

If approved, tavapadon would likely be available by prescription within a few months of the decision. Insurance coverage and pricing have not been announced. AbbVie has not signaled where it will price the drug, but as a brand-new once-daily oral therapy, it will not be cheap and the early years are likely to involve insurance prior authorizations.

How Tavapadon Fits Alongside What You Already Know

Tavapadon is not going to replace levodopa. Levodopa is still the most effective Parkinson's medication that exists, as we explain in our deeper article on what levodopa is and how it works. Nothing in the TEMPO data changes that.

What tavapadon could change is the dopamine agonist conversation. For decades, the trade-off has been: start a younger patient on an agonist to delay levodopa and the long-term motor fluctuations that come with it, but accept the real risk of impulse-control disorders and daytime sleep attacks. Tavapadon's data suggests a version of that trade-off where the impulse-control risk is much smaller.

For people already on levodopa with OFF time, tavapadon offers another add-on option. Today the choices are layering on a different agonist, adding a MAO-B or COMT inhibitor, switching to an extended-release levodopa formulation like Rytary, or considering device-based therapy like Vyalev or deep brain stimulation. Tavapadon would slot in as another tool in that conversation, with the advantage of being one pill a day.

Our article on levodopa vs dopamine agonists walks through how the older classes fit together, and our piece on carbidopa-levodopa formulations covers the levodopa side of the regimen.

Caveats

A few things to keep in mind.

First, real-world side-effect rates usually look worse than trial rates. The 1.4 percent impulse-control number in TEMPO-4 is encouraging, but the real test is years of broad post-marketing use.

Second, no head-to-head trial has compared tavapadon directly to pramipexole or ropinirole. The favorable comparison comes from holding TEMPO-4 numbers up against published estimates from older trials of different drugs in different populations. Cross-trial comparisons like that are suggestive, not definitive.

Third, tavapadon is a partial D1/D5 agonist, and we have less long-term safety data on this receptor approach than we do on the D2/D3 agonists that have been used for 30 years. Some side effects only show up after many years of use.

Fourth, the trials enrolled people up to age 80 but the average participant was younger than the average person living with Parkinson's. Tolerability and side-effect risk in the oldest, frailest patients will become clearer over time.

What This Means for Clinical Trial Searches

The pivotal TEMPO trials have completed enrollment, but the TEMPO-4 open-label extension and post-marketing studies may still be enrolling in some regions. Other D1-selective and partial dopamine agonists are also in earlier-stage trials, building on the tavapadon proof of concept. Browse tavapadon trials, dopamine agonist trials, or D1-targeted trials directly with keyword search.

If your family member is on an older dopamine agonist and dealing with impulse-control issues or sleep attacks, this is worth raising at the next neurology appointment. Our guide on how to talk to your neurologist about clinical trials walks through how to start that conversation, and our piece on how close is a cure for Parkinson's puts tavapadon in the context of the broader research pipeline.

Sources

AbbVie press release: AbbVie Submits New Drug Application to U.S. FDA for Tavapadon (September 29, 2025).
AbbVie press release: AbbVie Completes Acquisition of Cerevel Therapeutics (August 1, 2024).
TEMPO-1 (early PD, fixed dose, NCT04201093): ClinicalTrials.gov record.
TEMPO-2 (early PD, flexible dose, NCT04223193): ClinicalTrials.gov record.
TEMPO-3 (levodopa adjunct, NCT04542499): ClinicalTrials.gov record.
TEMPO-4 (open-label long-term safety, NCT04760769): ClinicalTrials.gov record.
American Academy of Neurology 2025 Annual Meeting — TEMPO-3 and TEMPO-4 results were presented at AAN 2025 (San Diego, April 2025).

Browse current Parkinson's clinical trials at Parkinson's Pathways. Updated daily.

Frequently Asked Questions

When will tavapadon be available?: AbbVie submitted the New Drug Application to the FDA in September 2025, and the FDA decision is expected in the first half of 2026. If approved, the drug would likely be available by prescription within a few months of the decision. Insurance coverage and pricing have not yet been announced.
How is tavapadon different from existing dopamine agonists like pramipexole or ropinirole?: Older agonists primarily activate D2 and D3 dopamine receptors. Tavapadon is selective for D1 and D5 receptors, a different family. In the TEMPO trials, this selectivity translated into lower rates of impulse-control disorders (about 1.4 percent) and daytime sleep attacks compared to what is typically seen with D2/D3 agonists. It is also once-daily, where most older agonists are taken two or three times a day.
Does tavapadon work for early Parkinson's or only advanced disease?: Both. The TEMPO program included monotherapy trials (TEMPO-1 and TEMPO-2) in people with early Parkinson's not yet on levodopa, and an add-on trial (TEMPO-3) in people with motor fluctuations on levodopa. All three Phase 3 trials hit their primary endpoint, so the FDA submission covers both populations.
Will tavapadon replace levodopa?: No. Levodopa is still the most effective Parkinson's medication that exists. Tavapadon is positioned as an alternative starting medication for early Parkinson's (to delay levodopa) and as an add-on for people already on levodopa who still have OFF time. The long-term TEMPO-4 extension reported that about 90 percent of participants did not need to start or increase levodopa during 14 to 20 months of tavapadon treatment.
Are there still tavapadon trials recruiting?: The pivotal Phase 3 trials have completed enrollment, but the TEMPO-4 open-label extension and post-marketing studies may still be enrolling participants in some regions. You can search current dopamine agonist trials at Parkinson's Pathways to see what is open today.